Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB), ...

Discover an informative webinar featuring leading researchers as they discuss advancements in biomarker discovery for Alzheimer's disease (AD) and related dementias. This webinar will showcase how the ...

For decades, diagnosing Parkinson’s disease has been a challenge, often requiring clinical evaluations, DaT SPECT scans, and ...

In January 2025, the Company presented at the 8th International Lewy Body Dementia Conference ... Patients with Alzheimer’s disease (AD) co-pathology, as assessed by plasma ptau181 levels ...

Existing research indicates that the accuracy of a Parkinson’s disease diagnosis hovers between 55% and 78% in the first five years of assessment. That’s partly because Parkinson’s sibling movement ...

Ten had AD pathology, two had FTLD (with negative tau immunocytochemistry) and two had mixed Lewy body and Alzheimer's pathology (one with cortical Lewy bodies, the other with Lewy bodies in the ...

Professor Im Joo Rhyu, director of the Korea University Graduate Program for Convergence & Translational Biomedicine and ...

In January 2025, the Company presented at the 8 th International Lewy Body Dementia Conference (ILBDC) in Amsterdam, the Netherlands. During 2025, CervoMed plans to also advance neflamapimod ...

(Nairobi) – Kenyan authorities should conclude and publicly announce the outcome of their investigation into the discovery of mutilated bodies at Mukuru Kwa Njenga quarry in July 2024 ...

After excluding reversible causes of dementia, there are four common dementia syndromes, which are Alzheimer's disease, vascular dementia, dementia with Lewy body, and frontotemporal dementia.

The cells that make up the walls of the finest of all lymphatic vessels have a lobate, oak leaf-like shape that makes them ...